The available CY 2023 performance period/2025 MIPS payment year data identifies performance category submissions by non-Shared Savings Program ACO APM Entities
Were here to support you, and the more we know about how youre feeling, the better we can tailor your treatment
J Endourol 2003
Payandeh Z, Yarahmadi M, Nariman-Saleh-Fam Z, Tarhriz V, Islami M, Aghdam AM, et al
CONCLUSION In summary, this review highlights the key effects of GLP-1 agonists on modifying alcohol-seeking behavior, providing support for their potential use as an adjunct to treatment while raising ideas for future research, such as their effect on AUD in association with different sets of alleles, in various clinical settings and a wider set of the population
Additionally, the appetite-suppressing effects of both drugs may lead to inadequate nutritional intake or exacerbate weight loss beyond therapeutic targets, which could be harmful in some individuals